InvestSMART

Epsilon Healthcare Limited (ASX: EPN) - Announcements

- Current share price for EPN : $0.026

ASX company news and announcements for Epsilon Healthcare Limited (EPN) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Epsilon Healthcare Limited (EPN) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Epsilon Healthcare Limited (EPN), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Epsilon Healthcare Limited (EPN)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$10 Epsilon Healthcare Renewal of Medicinal Cannabis Permit 6 May 2025 10:14AM $0.024 $0.026 risen by 8.33%
$10 Quarterly Activities/Appendix 4C Cash Flow Report 5 May 2025 2:40PM $0.024 $0.026 risen by 8.33%
$10 Notice of Annual General Meeting/Proxy Form 28 Apr 2025 8:24AM $0.024 $0.026 risen by 8.33%
$10 Long Term Suspended Entities 9 Apr 2025 4:18PM $0.024 $0.026 risen by 8.33%
$10 Quarterly Activities/Appendix 4C Cash Flow Report 3 Apr 2025 5:13PM $0.024 $0.026 risen by 8.33%
$10 Epsilon Pharma Deed of Company Arrangement Effectuated 3 Apr 2025 5:10PM $0.024 $0.026 risen by 8.33%
$10 Quarterly Activities/Appendix 4C Cash Flow Report 3 Apr 2025 9:43AM $0.024 $0.026 risen by 8.33%
$10 Corporate Governance Statement 28 Mar 2025 4:28PM $0.024 $0.026 risen by 8.33%
$10 Appendix 4G 28 Mar 2025 4:27PM $0.024 $0.026 risen by 8.33%
$10 Full Year Statutory Accounts 28 Mar 2025 1:48PM $0.024 $0.026 risen by 8.33%
$10 Appendix 4E - 31 December 2023 28 Feb 2025 1:39PM $0.024 $0.026 risen by 8.33%
$10 Updated and Amended Dec 2023 Quarterly Activities Report 28 Feb 2025 12:27PM $0.024 $0.026 risen by 8.33%
$10 Epsilon Clinics Deed of Company Arrangement Effectuated 26 Feb 2025 4:01PM $0.024 $0.026 risen by 8.33%
$10 Quarterly Activities Report 31 Jan 2025 2:42PM $0.024 $0.026 risen by 8.33%
$10 Quarterly Appendix 4C Cash Flow Report 31 Jan 2025 2:42PM $0.024 $0.026 risen by 8.33%
$10 Long Term Suspended Entities 22 Jan 2025 4:20PM $0.024 $0.026 risen by 8.33%
$10 Application for quotation of securities - EPN 27 Dec 2024 10:03AM $0.024 $0.026 risen by 8.33%
$10 Cancel - Notification regarding unquoted securities - EPN 27 Dec 2024 10:00AM $0.024 $0.026 risen by 8.33%
$10 Notification regarding unquoted securities - EPN 24 Dec 2024 9:57AM $0.024 $0.026 risen by 8.33%
$10 Placement 19 Dec 2024 4:47PM $0.024 $0.026 risen by 8.33%
$10 Proposed issue of securities - EPN 19 Dec 2024 11:45AM $0.024 $0.026 risen by 8.33%
$10 Company Update 19 Dec 2024 11:45AM $0.024 $0.026 risen by 8.33%
$10 Letter to Shareholders 16 Dec 2024 3:52PM $0.024 $0.026 risen by 8.33%
$10 Long Term Suspended Entities 18 Oct 2024 4:15PM $0.024 $0.026 risen by 8.33%
$10 Epsilon Pharma and Epsilon Clinics - Completion of DOCA 8 Oct 2024 12:44PM $0.024 $0.026 risen by 8.33%

76 - 100 of 253 results

Page 4 of 11

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.